INLYTA for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 71 adverse event reports in the FDA FAERS database where INLYTA was used for Renal cell carcinoma.
Most Reported Side Effects for INLYTA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 97 | 19.2% | 30 | 10 |
| Diarrhoea | 96 | 19.0% | 7 | 11 |
| Death | 75 | 14.8% | 75 | 4 |
| Fatigue | 68 | 13.4% | 3 | 8 |
| Nausea | 45 | 8.9% | 3 | 5 |
| Renal cancer | 45 | 8.9% | 6 | 4 |
| Dysphonia | 40 | 7.9% | 0 | 5 |
| Decreased appetite | 33 | 6.5% | 3 | 5 |
| Asthenia | 29 | 5.7% | 4 | 8 |
| Hypertension | 26 | 5.1% | 1 | 7 |
| Vomiting | 26 | 5.1% | 4 | 4 |
| Weight decreased | 26 | 5.1% | 3 | 2 |
| Blood pressure increased | 22 | 4.4% | 0 | 3 |
| Constipation | 22 | 4.4% | 0 | 0 |
| Pain in extremity | 21 | 4.2% | 1 | 3 |
Other Indications for INLYTA
Renal cancer (236)
Metastatic renal cell carcinoma (46)
Renal cancer metastatic (22)
Neoplasm malignant (15)
Malignant urinary tract neoplasm (7)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)